Antonio Guerrero-Sola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio Guerrero-Sola has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
L. Galán
Servicio de Neurología, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, España
5 shared publications- Jordi A. Matias-Guiu
Hospital Clinico San Carlos
4 shared publications - Ulises Gómez-Pinedo
Laboratorio de Neurobiología y Terapias Avanzadas, Instituto de Neurociencias, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain
4 shared publications C. Ramírez-Ramos
Service of Neurology, Hospital Universitario San Carlos, Madrid, Spain
3 shared publications- Carlos Gomez-Escalonilla
Neurology, Hospital Clinico San Carlos, Madrid, Spain
3 shared publications F. J. Jiménez-Jiménez
Department of Medicine-Neurology, University of Alcalá, Alcalá de Henares
3 shared publications
Latest Publications
- Open Access
- 1 May 2018
- Published by Elsevier in Neurología
- Vol. 33 (4) , 211-223
La infusión intracerebroventricular prolongada de líquido cefalorraquídeo procedente de pacientes con esclerosis lateral amiotrófica provoca cambios histológicos en el cerebro y la médula espinal de la rata similares a los hallados en la enfermedad
- 1 May 2018
- Published by Elsevier in Neurología
- Vol. 33 (4) , 211-223
Open AccessLa infusión intracerebroventricular prolongada de líquido cefalorraquídeo procedente de pacientes con esclerosis lateral amiotrófica provoca cambios histológicos en el cerebro y la médula espinal de la rata similares a los hallados en la enfermedad
- 1 June 2017
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 136 (1) , 79
Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis and sample size
- 1 June 2017
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 136 (1) , 79
Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis and sample size
- 29 December 2016
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 136 (3) , 212-216
Cerebrospinal fluid cytotoxicity does not affect survival in amyotrophic lateral sclerosis
Cerebrospinal fluid (CSF) from some patients with amyotrophic lateral sclerosis (ALS) has been demonstrated to significantly reduce the neuronal viability of primary cell cultures of motor neurons. We aimed to study the potential clinical consequences associated with the cytotoxicity of CSF in a cohort of patients with ALS. We collected CSF from thirty-one patients with ALS. We analysed cytotoxicity by incubating it into the primary cultures of motor cortex neurons. Neural viability was quantified after 24 hours using the colorimetric MTT reduction assay. All patients were followed up from the moment of diagnosis to death, and a complete evaluation during disease progression and survival was performed, including gastrostomy and respiratory assistance. Twenty-one patients (67.7%) presented a cytotoxic CSF. There were no significant differences between patients with and without cytotoxicity regarding mean time from symptom onset to the diagnosis, from the diagnosis to death, from the diagnosis to respiratory assistance with BIPAP, from diagnosis to gastrostomy and from the onset of symptoms to death. In Cox regression analysis, bulbar onset, but not cytotoxicity, gender or age at onset, was associated with a lower risk of survival. Cerebrospinal fluid cytotoxicity was not associated with differential survival rates. This suggests that the presence of cytotoxicity in CSF, measured through neuronal viability in primary cultures of motor cortex neurons, could reflect different mechanisms of the disease, but it does not predict disease outcome.
- 29 December 2016
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 136 (3) , 212-216
Cerebrospinal fluid cytotoxicity does not affect survival in amyotrophic lateral sclerosis
Cerebrospinal fluid (CSF) from some patients with amyotrophic lateral sclerosis (ALS) has been demonstrated to significantly reduce the neuronal viability of primary cell cultures of motor neurons. We aimed to study the potential clinical consequences associated with the cytotoxicity of CSF in a cohort of patients with ALS. We collected CSF from thirty-one patients with ALS. We analysed cytotoxicity by incubating it into the primary cultures of motor cortex neurons. Neural viability was quantified after 24 hours using the colorimetric MTT reduction assay. All patients were followed up from the moment of diagnosis to death, and a complete evaluation during disease progression and survival was performed, including gastrostomy and respiratory assistance. Twenty-one patients (67.7%) presented a cytotoxic CSF. There were no significant differences between patients with and without cytotoxicity regarding mean time from symptom onset to the diagnosis, from the diagnosis to death, from the diagnosis to respiratory assistance with BIPAP, from diagnosis to gastrostomy and from the onset of symptoms to death. In Cox regression analysis, bulbar onset, but not cytotoxicity, gender or age at onset, was associated with a lower risk of survival. Cerebrospinal fluid cytotoxicity was not associated with differential survival rates. This suggests that the presence of cytotoxicity in CSF, measured through neuronal viability in primary cultures of motor cortex neurons, could reflect different mechanisms of the disease, but it does not predict disease outcome.
- Open Access
- 8 November 2016
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 7, 195
Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases
Background: Several findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND). Objective: Considering that dementia is one of the most frequently non-motor symptoms in ALS and that hippocampus is one of the brain areas with greater presence of amyloid related changes in neurodegenerative diseases, our aim was to analyse the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-FTD. Methods: We included 9 patients with MND and 4 controls. Immunohistochemical studies and confocal microscopy were used to analyse the expression of APP, TDP-43, pho-TDP-43, Aβ, AICD peptide, Fe65 protein, and pho-TAU in the hippocampus of 7 patients with ALS, 2 patients with ALS-FTD, and 4 controls. These findings were correlated with clinical data. Results: Patients displayed increased expression of APP and Aβ peptide. The latter was correlated with cytoplasmic pho-TDP-43 expression. We also found decreased Fe65 expression. A parallel increase in AICD expression was not found. Patients showed increased expression of pho-TAU in the hippocampus. Findings were similar in patients with ALS and those with ALS-FTD, though more marked in the latter group. Conclusion: Post-mortem analyses showed that the amyloid cascade is activated in the hippocampus of patients with MND and correlated with cytoplasmic pho-TDP-43 expression. The number of intra- or extracellular aggregates of Aβ peptides was not significant.
- 8 November 2016
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 7, 195
Open AccessImmununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases
Background: Several findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND). Objective: Considering that dementia is one of the most frequently non-motor symptoms in ALS and that hippocampus is one of the brain areas with greater presence of amyloid related changes in neurodegenerative diseases, our aim was to analyse the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-FTD. Methods: We included 9 patients with MND and 4 controls. Immunohistochemical studies and confocal microscopy were used to analyse the expression of APP, TDP-43, pho-TDP-43, Aβ, AICD peptide, Fe65 protein, and pho-TAU in the hippocampus of 7 patients with ALS, 2 patients with ALS-FTD, and 4 controls. These findings were correlated with clinical data. Results: Patients displayed increased expression of APP and Aβ peptide. The latter was correlated with cytoplasmic pho-TDP-43 expression. We also found decreased Fe65 expression. A parallel increase in AICD expression was not found. Patients showed increased expression of pho-TAU in the hippocampus. Findings were similar in patients with ALS and those with ALS-FTD, though more marked in the latter group. Conclusion: Post-mortem analyses showed that the amyloid cascade is activated in the hippocampus of patients with MND and correlated with cytoplasmic pho-TDP-43 expression. The number of intra- or extracellular aggregates of Aβ peptides was not significant.
- Open Access
- 28 March 2016
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 22 (7) , 568-576
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
Summary: Aims: Patients with Fabry disease ( FD ) characteristically develop peripheral neuropathy at an early age, with pain being a crucial symptom of underlying pathology. However, the diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practical guidance on the diagnosis and management of pain in FD is needed. Methods: In 2014, experts met to discuss recent advances on this topic and update clinical guidance. Results: Emerging disease‐specific tools, including FabryScan, Fabry‐specific Pediatric Health and Pain Questionnaire, and Würzburg Fabry Pain Questionnaire, and more general tools like the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in patients with FD . These tools can be complemented by more objective and quantifiable sensory testing. In male and female patients of any age, pain related to FD can be an early indication to start disease‐specific enzyme replacement therapy before potentially irreversible organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients. Treatment should include: (a) enzyme replacement therapy controlling the progression of underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) lifestyle modifications.
- 28 March 2016
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 22 (7) , 568-576
Open AccessPain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
Summary: Aims: Patients with Fabry disease ( FD ) characteristically develop peripheral neuropathy at an early age, with pain being a crucial symptom of underlying pathology. However, the diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practical guidance on the diagnosis and management of pain in FD is needed. Methods: In 2014, experts met to discuss recent advances on this topic and update clinical guidance. Results: Emerging disease‐specific tools, including FabryScan, Fabry‐specific Pediatric Health and Pain Questionnaire, and Würzburg Fabry Pain Questionnaire, and more general tools like the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in patients with FD . These tools can be complemented by more objective and quantifiable sensory testing. In male and female patients of any age, pain related to FD can be an early indication to start disease‐specific enzyme replacement therapy before potentially irreversible organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients. Treatment should include: (a) enzyme replacement therapy controlling the progression of underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) lifestyle modifications.
- 1 July 2014
- Published by Elsevier in Neurología
- Vol. 29 (6) , 346-352
Cambios celulares producidos por la citotoxicidad del líquido cefalorraquídeo de pacientes con esclerosis lateral amiotrófica sobre cultivos de neuronas motoras
- 1 July 2014
- Published by Elsevier in Neurología
- Vol. 29 (6) , 346-352
Cambios celulares producidos por la citotoxicidad del líquido cefalorraquídeo de pacientes con esclerosis lateral amiotrófica sobre cultivos de neuronas motoras
- 15 July 2011
- Published by Elsevier in Neuroscience Letters
- Vol. 499 (1) , 9-13
Subventricular zone in motor neuron disease with frontotemporal dementia
- 15 July 2011
- Published by Elsevier in Neuroscience Letters
- Vol. 499 (1) , 9-13
Subventricular zone in motor neuron disease with frontotemporal dementia
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5323-5326
Protocolo diagnóstico de las alteraciones motoras distales
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5323-5326
Protocolo diagnóstico de las alteraciones motoras distales
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5310-5317
Trastornos musculares caracterizados por calambres, espasmos, mialgias e intolerancia al ejercicio
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5310-5317
Trastornos musculares caracterizados por calambres, espasmos, mialgias e intolerancia al ejercicio
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5283-5290
Distrofias musculares y miopatías congénitas
- 1 May 2011
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 10 (78) , 5283-5290
Distrofias musculares y miopatías congénitas